David Steensma: Lentiviral vectors construct integration into TP53
David Steensma, Chief Medical Officer at Ajax Therapeutics, posted on X about recent paper by Karlo Perica et al., titled “CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53” published on The New England Journal of Medicine.
Authors: Karlo Perica, Nayan Jain, Michael Scordo, Ruchi Patel, Ozgur Can Eren, Utsav Patel, Gunes Gundem, Dylan Domenico, Sneha Mitra, Nicholas D. Socci, John K. Everett, Aoife M. Roche, Angelina Petrichenko, Gunjan L. Shah, Maria E. Arcila, Laetitia Borsu, Jae H. Park, Steven M. Horwitz, Sergio A. Giralt, Ahmet Dogan, Christina Leslie, Elli Papaemmanuil, Frederic D. Bushman, Saad Z. Usmani, Michel Sadelain, and Sham Mailankody.
“When reports emerged in 2023 of T cell secondary malignancies in CAR-T treated patients, mechanism was unclear. New MSKCC report The New England Journal of Medicine describes Lentiviral vectors (LV) construct integration into TP53. Likely v rare event but does inform debate about using CAR-T early vs later.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023